Compugen Ltd. Aktie News

Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered programs Monetization includes an upfront payment of $65 million and a potential additional $25 million upon reaching the next milestone Compugen retains majority of royalties preserving potential ...

Compugen Ltd. ( CGEN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Yvonne Naughton - Head of Investor Relations & Corporate Communications Eran Ophir - CEO & Director David Silberman - Chief Financial Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Daina Graybos...

COM701 Phase 1 data presented at ESMO 2025 characterized patients who derived clinical benefit and informed the design of the ongoing MAIA-ovarian platform trial Enrolling patients in the U.S., Israel and France in the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in patients with platinum sensitive ovarian cancer with interim analysis now estimated in Q1 2027 SITC 2025 – Co...

HOLON, Israel , Nov. 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2025 Healthcare Conference in New York City.

HOLON, Israel , Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that the Company will release its third quarter 2025 financial results on Monday November 10, 2025, before the U.S. financial markets open.

Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum sensitive ovarian cancer HOLON, Israel , Oct. 13, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today annou...

HOLON, Israel , Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML today announced, that a trial in progress of the first in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in participants with advanced solid malignancies will b...

HOLON, ISRAEL , Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd.